BSE will suspend trading in Chemcel Biotech Limited’s securities for non-compliance of several clauses that are part of the listing agreement. Trading in the shares will be suspended with effect from March 21, 2013. In case the company complies with all the provisions of the listing agreement on or before March 13, 2013, then trading in the shares will be suspended for five days up to March 28, 2013.

Chemcel Biotech Limited reported unaudited consolidated and standalone earnings results for the second quarter and six months ended September 30, 2012. For the quarter, on a consolidated basis, the company reported total income from operations of INR 121,559,000 against INR 144,086,000 for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 5,813,000 against INR 10,167,000 for the same period last year. Profit from ordinary activities before tax was INR 3,001,000 against INR 5,700,000 for the same period last year. Net profit for the period was INR 3,001,000 or INR 0.11 per basic and diluted share against INR 5,700,000 or INR 0.20 per basic ad diluted share for the same period last year. For the six months, on a consolidated basis, the company reported total income from operations of INR 123,222,000 against INR 145,558,000 for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 6,412,000 against INR 5,356,000 for the same period last year. Profit from ordinary activities before tax was INR 790,000 against INR 253,000 for the same period last year. Net profit for the period was INR 790,000 or INR 0.03 per basic and diluted share against INR 253,000 or INR 0.01 per basic ad diluted share for the same period last year. For the quarter, on a standalone basis, the company reported total income from operations of INR 121,559,000 against INR 144,086,000 for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 5,833,000 against INR 10,207,000 for the same period last year. Profit from ordinary activities before tax was INR 3,021,000 against INR 5,740,000 for the same period last year. Net profit for the period was INR 3,021,000 or INR 0.11 per basic and diluted share against INR 5,740,000 or INR 0.21 per basic ad diluted share for the same period last year. For the six months, on a standalone basis, the company reported total income from operations of INR 123,222,000 against INR 145,558,000 for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 6,452,000 against INR 5,396,000 for the same period last year. Profit from ordinary activities before tax was INR 830,000 against INR 272,000 for the same period last year. Net profit for the period was INR 830,000 or INR 0.03 per basic and diluted share against INR 272,000 or INR 0.01 per basic ad diluted share for the same period last year.

Chemcel Biotech Limited, Board Meeting, Nov 15, 2012. Agenda: To approve the unaudited consolidated and standalone earnings results for the second quarter and six months ended September 30, 2012.